Kisspeptin-54

PCOS Ovulation Induction

Women with polycystic ovary syndrome represent a population at particular risk for OHSS during fertility treatment. Jayasena et al. (2014) showed that kisspeptin-54 administration to women with PCOS induced dose-dependent LH secretion, demonstrating preserved kisspeptin sensitivity despite the dysregulated HPG axis characteristic of PCOS. This suggests kisspeptin could provide a safer ovulation induction strategy in PCOS patients, where the multiple developing follicles create high OHSS susceptibility with conventional gonadotropin protocols.

Puberty Disorders

The discovery that inactivating mutations in KISS1R cause idiopathic hypogonadotropic hypogonadism established kisspeptin as essential for puberty. Conversely, activating KISS1R mutations are associated with precocious puberty. Research has explored kisspeptin administration as a diagnostic tool in distinguishing constitutional delay of puberty from pathological hypogonadotropic hypogonadism, with kisspeptin-stimulated LH response serving as a functional test of the GnRH axis.

Reproductive Neuroscience

Kisspeptin neurons have been identified as critical nodes in the KNDy (kisspeptin/neurokinin B/dynorphin) network that generates pulsatile GnRH release. Research into this network has expanded understanding of how metabolic status, lactation, and aging modulate fertility through kisspeptin neuron activity.

IVF Oocyte Maturation Trigger

The most clinically advanced application of kisspeptin-54 is as a trigger for final oocyte maturation in IVF cycles. Abbara et al. (2015) demonstrated that a single subcutaneous injection of kisspeptin-54 (1.6-12.8 nmol/kg) effectively triggered oocyte maturation in women undergoing IVF, with egg numbers and maturation rates comparable to standard HCG triggers. Critically, no cases of clinically significant OHSS were observed, even in high-responder patients who would be at elevated risk with HCG. Abbara et al. (2017) further confirmed kisspeptin's safety in a larger cohort, reporting live birth rates with no OHSS, establishing kisspeptin as a viable physiological alternative for patients at high OHSS risk.

IVF Oocyte Maturation Trigger and OHSS Prevention

Abbara et al. (2015) conducted a proof-of-concept study using kisspeptin-54 (9.6 nmol/kg SC) as an alternative to hCG for triggering oocyte maturation in 53 women at high risk of ovarian hyperstimulation syndrome (OHSS) during IVF. The kisspeptin trigger produced adequate oocyte maturation rates (71% mature oocytes) with zero cases of OHSS, compared to an expected 20-30% OHSS rate with standard hCG trigger. The key advantage is that kisspeptin-54 induces a physiological, self-limited LH surge lasting ~12 hours, unlike hCG which produces prolonged receptor activation (half-life ~33 hours) that drives the vascular leak, fluid shifts, and electrolyte imbalances underlying OHSS.

Abbara et al. (2018) followed up with a dose-finding study demonstrating that higher kisspeptin-54 doses (12.8 nmol/kg) improved oocyte maturation rates to 82% while maintaining the OHSS-free safety profile. Live birth rates in the kisspeptin-triggered cycles were comparable to those achieved with GnRH agonist trigger protocols.

Hypothalamic Amenorrhea

Jayasena et al. (2014) administered kisspeptin-54 (6.4 nmol/kg SC twice daily for 2 weeks) to 10 women with hypothalamic amenorrhea. Treatment restored pulsatile LH secretion in 7 of 10 women and increased LH pulse frequency from 0.2 to 2.8 pulses per 8 hours. This demonstrated that the GnRH neuronal network remains responsive to kisspeptin stimulation even after prolonged quiescence, and established kisspeptin-54 as a potential therapeutic for functional hypothalamic amenorrhea.

Psychosexual Effects

Comninos et al. (2017) conducted a landmark randomized, double-blind, placebo-controlled crossover fMRI study in 29 healthy heterosexual men. Kisspeptin-54 infusion (1 nmol/kg/h IV for 75 minutes) enhanced limbic brain activity in response to sexual and romantic images, specifically in the globus pallidus, posterior cingulate cortex, and thalamus. Subjects also reported increased penile tumescence during sexual image viewing. This was the first evidence that kisspeptin modulates human sexual brain processing beyond its reproductive endocrine effects.

Comninos et al. (2022) extended these findings, showing kisspeptin-54 modulates both sexual and emotional brain processing, with effects on negative mood reduction and enhanced responses to bonding-related stimuli. These psychosexual effects position kisspeptin-54 as a potential therapy for desire and arousal disorders with psychological components.

Gonadotropin Stimulation in Healthy Volunteers

Dhillo et al. (2005) administered the first human doses of kisspeptin-54 (0.1-1.0 nmol/kg IV) to healthy male volunteers (n=6), demonstrating robust, dose-dependent LH and FSH release peaking within 30-60 minutes. LH increased up to 8-fold over baseline at the highest dose. This pivotal study confirmed that the kisspeptin-KISS1R system regulates gonadotropin release in humans and opened the door to clinical applications.

Male Reproductive Function

George et al. (2011) characterized the gonadotropin response to kisspeptin-54 across the male reproductive axis. Single SC bolus doses (0.1-3.2 nmol/kg) produced dose-dependent LH increases with a ceiling effect at ~1.6 nmol/kg. Testosterone rose secondarily, peaking 4-6 hours after kisspeptin-54 administration. These data established kisspeptin-54's ability to stimulate the entire HPG axis in men.